Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO
Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO
comparing the outcome of low-intensity shock wave therapy (Li-SWT) versus solifenacin on
 persistent storage symptoms after transurethral surgery for benign prostatic obstruction
 (BPO)
Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS)
 in aging men including both voiding and storage symptoms. After prostatectomy, 20-30% of the
 patients still have persistent storage symptoms. The pathophysiology of persistent storage
 symptoms after surgical relief of benign prostatic obstruction (BPO) remains unclear. It may
 be due to bladder changes produced by long standing bladder outlet obstruction (BOO)
 including bladder ischemia and denervation or it may be related to other factors rather than
 preoperative BOO such as aging, chronic inflammation or a subtle neurological disorder.

 After exclusion of urinary tract infection (UTI) and BOO, antimuscarinics are the commonly
 used medications for post-prostatectomy persistent storage symptoms. However, these
 medications are associated with side effects which may interfere with the patient compliance.

 Low-intensity shock wave therapy (Li-SWT) is a non invasive procedure that has a beneficial
 effect in promoting revascularization and enhancing tissue regeneration. It has been applied
 to the penis for erectile dysfunction and to the perineum for chronic pelvic pain syndrome
 (CPPS) with encouraging results. In a rat model, it has been reported that defocused Li-SWT
 leads to improvement of bladder innervation and vascularization.

 Based on the previously mentioned studies, the investigators hypothesized that Li-SWT can
 offer benefit in improvement of persistent storage symptoms after surgical relief of BPO. In
 the present study, the investigators will evaluate the effect of Li-SWT on persistent storage
 symptoms after transurethral surgery for BPO compared to antimuscarinics in a randomized
 controlled trial (RCT).
Inclusion Criteria:

 -  Patients have to fulfill all the following criteria to be included in the study:

 1. Ability to give informed consent and reply to questionnaires.

 2. Average urgency episodes per 24 hrs ≥ 1 and average daytime frequency ≥ 8 during
 the baseline 3-day voiding diary.

 3. Relief of BOO as proved by non-invasive uroflowmetry, pressure flow study (PFS)
 or urethrocystoscopy.

 Exclusion Criteria:

 -  Patients who have any of the following will be excluded from the study:

 1. Untreated UTI.

 2. BOO such as bladder neck contracture (BNC), residual obstructing adenoma or
 urethral stricture.

 3. Neurogenic lower urinary tract dysfunction (LUTD).

 4. Uncontrolled diabetes mellitus.

 5. Depression or any psychogenic disorders.

 6. Prior radiation therapy to the pelvic area.

 7. History of prostate cancer, bladder tumor or intravesical Bacillus Calmette
 Guerin (BCG) therapy.

 8. Poor coagulopathy.

 9. Severe cardiovascular disease.